Haley Naik, M.D., Discusses Hidradenitis Suppurativa at Annual AAD Meeting
Haley Naik, M.D., associate professor of dermatology at the University of California, San Francisco, School of Medicine, led a discussion about hidradenitis suppurativa today at the annual American Academy of Dermatology meeting in New Orleans.
Haley Naik, M.D., associate professor of dermatology at the University of California, San Francisco, School of Medicine, led a discussion about hidradenitis suppurativa today at the annual American Academy of Dermatology meeting in New Orleans.
Naik says the growing prevalence of the disease is likely the result of increased diagnosis and public awareness and not a population increase in the condition.
Although studies have shown an association between hidradenitis suppurativa and metabolic disorders, Naik said the evidence does not point toward a causal relationship and that weight loss.
Humira (adalimumab) is approved as a treatment for hidradentis suppurativa. Naik, who said it may be time for clinicians to consider using biologics earlier in the course of hidradenitis suppurativa, said the launching of biosimilars to Humira this year may improves access to treatment for the condition.
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.
Read More
